Endothelin-1 and cardiovascular diseases;Endotheline-1 et pathologies cardiovasculaires

Revue de Medecine Interne

Volumn 20, Issue 7, 1999, Pages 589-596

  Cracowski, J L ^a   Stanke, F ^a   Bessard, G ^a  

^a UNIV GRENOBLE ALPES   (France)

Author keywords

Endothelins; Heart; Heart failure; Hypertension; Pulmonary hypertension; Vessels

Indexed keywords

ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; ENDOTHELIN RECEPTOR;

CORONARY ARTERY DISEASE; ENDOTHELIUM CELL; HEART FAILURE; HUMAN; HYPERTENSION; PATHOPHYSIOLOGY; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; REVIEW; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG ANTAGONISM; PHYSIOLOGY;

CARDIOVASCULAR DISEASES; CLINICAL TRIALS; ENDOTHELIN-1; HUMANS; MUSCLE, SMOOTH, VASCULAR; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B; RECEPTORS, ENDOTHELIN;

EID: 0033165794     PISSN: 02488663     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0248-8663(99)80108-8     Document Type: Article

References (58)

1. Hickey KA, Rubanyi G, Paul RJ, Highsmith R. Characterization of a coronary vasoconstrictor produced by endothelial cells. Am J Physiol 1985 ; 248 (5Pt1 ): 550-6.
2. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988 ; 332: 411-5.
3. Inoue A, Yanagisawa M, Kimura S, Kasuya Y, Miyauchi T, Goto K, et al. The human endothelin family: Three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA 1989 ; 86: 2863-7.
4. Harrison VJ, Barnes K, Turner AJ, Wood E, Corder R, Vane JR. Identification of endothelin 1 and big endothelin 1 in secretory vesicles isolated from bovine aortic endothelial cells. Proc Natl Acad Sci USA 1995 ; 92 : 6344-8.
5. Kimura S, Kasuya Y, Sawamura T, Shinmi O, Sugita Y, Yanagisawa M. et al. Conversion of big endothelin-1 to 21-residue endothelin-1 is essential for expression of full vasoconstrictor activity: Structure-activity relationships of big endothelin-1. J Cardiovasc Pharmacol 1989 ; 13 Suppl 5 : 5-7.
6. Xu D, Emoto N, Giaid A, Slaughter C, Kaw S, deWit D, et al. ECE-1: A membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1. Cell 1994 ; 78 : 473-85.
7. Shimada K, Takahashi M, Ikeda M, Tanzawa K. Identification and characterization of two isoforms of an endothelin-converting enzyme-1. FEBS Lett 1995 ; 371 : 140-4.
8. Wagner OF, Christ G, Wojta J, Vierhapper S, Parzer S, Nowotny PJ, et al. Polar secretion of endothelin-1 by cultured endothelial cells. J Biol Chem 1992 ; 267 : 16066-8.
9. Dupuis J, Stewart DJ, Cernacek P, Gosselin G. Human pulmonary circulation is an important site for both clearance and production of endothelin-1. Circulation 1996 ; 94 : 1578-84.
10. Hosoda K, Nakao K, Hiroshi A, Suga S, Ogawa Y, Mukoyama M, et al. Cloning and expression of human endothelin-1 receptor cDNA. FEBS Lett 1991 ; 287 : 23-6.
11. Michael JR, Markewitz BA. Endothelins and the lung. Am J Respir Crit Care Med 1996 ; 154 : 555-81.
12. Kurihara Y, Kurihara H, Oda H, Maemura K, Nagai R, Ishikawa T, et al. Aortic arch malformations and ventricular septal defect in mice deficient in endothelin-1. J Clin Invest 1995 ; 96 : 293-300.
13. Haynes W, Webb D. Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet 1994 ; 344 : 852-4.
14. Berrazueta JR, Bhagat K, Vallance P, Masallister RJ. Dose and time-dependency of the dilator effects of the endothelin antagonist, BQ-123, in the human forearm. Br J Clin Pharmacol 1997 ; 44 : 569-71.
15. Haynes WG, Ferro CJ, O'Kayne KP, Somerville D, Lomax CC, Webb DJ. Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in man. Circulation 1996 ; 93 : 1860-70.
16. Love MP, Ferro CJ, Haynes WG, Webb DJ, McMurray JJ. Selective or non selective endothelin receptor blockade in chronic heart failure. Circulation 1996 ; 94 (suppl I) : 2899-900.
17. Verhaar MC, Strachan FE, Newsby DE, Cruden NL, Koomans HA, Rabelink TJ, et al. Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation 1998 ; 97 : 752-6.
18. Wei CM, Lerman A, Rodeheffer RJ, McGregor CG, Brandt RR, Wright S, et al. Endothelin in human congestive heart failure. Circulation 1994 ; 89 : 1580-6.
19. Rodeheffer RJ, Lerman A, Heublein DM, Burnet JC. Increased plasma concentrations of endothelin in chronic heart failure in humans. Mayo Clin Proc 1992 ; 67 : 719-24.
20. Cody RJ, Haas GJ, Binkley PF, Capers Q, Kelley R. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation 1992 ; 85 : 504-9.
21. Krum H, Goldsmith R, Wilshire-Clement M, Miller M, Packer M. Role of endothelin in the exercise intolerance of chronic heart failure. Am J Cardiol 1995 ; 75 : 1282-3.
22. Pacher R, Stanek B, Hülsmann M, Koller-Strametz J, Berger R, Schuller M, et al. Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J Am Coll Cardiol 1996 ; 27 : 633-41.
23. Mulder P, Richard V, Derumeaux G, Hogie M, Henry JP, Lallemand F, et al. Role of endogenous endothelin in chronic heart failure. Circulation 1997 ; 96 : 1976-82.
24. Love MP, Haynes WG, Gray GA, Webb DJ, McMurray JJ. Vasodilator effects of endothelin-converting enzyme inhibition and endothelin ETA receptor blockade in chronic heart failure patients treated with ACE inhibitors. Circulation 1996 ; 94 : 2131-7.
25. Love MP, Haynes WG, Gray GA, Webb DJ, McMurray JJ. Endothelin receptor function in capacitance vessels of patients with chronic heart failure. Circulation 1996 ; 94 (suppl ) : 2899-900.
26. Dagassan PH, Breu V, Clozel M, Kunzli A, Vogt P, Turina M, et al. Up-regulation of endothelin-B receptors in atherosclerotic human coronary arteries. J Cardiovasc Pharmacol 1996 ; 27 : 147-53.
27. Pönicke K, Vogelsang M, Heinroth M, Becker K, Zolk O, Böhm M, et al. Endothelin receptors in the failing and nonfailing human heart. Circulation 1998 ; 97 : 744-51.
28. Kiowski W, Sütsch G, Hunziker P, Muller P, Kim J, Oechslin E, et al. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet 1995 ; 346 : 732-6.
29. Kiowski W, Suetsch G, Van XW, Strobel W, Rickenbacher P, Hunziker P, et al. Neurohormonal effect of endothelin-1 receptor antagonist therapy in patients with chronic heart failure [abstract]. Circulation 1997 ; 96 (suppl I) : 93.
30. Brunner HR. Endothelin inhibition as a biologic target for treating hypertension. Am J Hypertens 1998 ; 11 : 103-9.
31. Florijn KW, Derkx FH, Visser W, Hofman HJ, Rosmalen FM, Wallenburg HC, et al. Elevated plasma levels of endothelin in pre-eclampsia. J Hypertens 1991 ; 9 : 166-7.
32. Shichiri M, Hirata Y, Ando K, Emori T, Ohta K, Kimolo S, et al. Plasma endothelin levels in hypertension and chronic renal failure. Hypertension 1990 ; 15 : 493-6.
33. Yoshida K, Yasujima M, Kohzuki M, Kanazawa M, Yoshinaga K, Abe K. Endothelin-1 augments pressor response to angiotensin II infusion in rats. Hypertension 1992 ; 20 : 292-7.
34. Donckier JE, Stoleru L, Hayashida W, Van Mechelen H, Selvais P, Galanti L, et al. Role of endogenous endothelin-1 in experimental renal hypertension in dogs. Circulation 1995 ; 92 : 106-13.
35. Donckier JE, Massart PE, Hodeige D, Van Mechelen H, Clozel JP, Laloux O, et al. Additional hypotensive effect of endothelin-1 receptor antagonism in hypertensive dogs under angiotensin-converting enzyme inhibition. Circulation 1997 ; 96 : 1250-6.
36. Krum H, Viskoper RJ, Lacourciere Y, Budde M, Charlon V. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. N Engl J Med 1998 ; 338 : 784-90.
37. Stewart DJ, Kubac G, Costello KB, Cernacek P. Increased plasma endothelin-1 in the early hours after myocardial infarction. J Am Coll Cardiol 1991 ; 18 : 38-43.
38. Ray SG, McMurray JJ, Morton JJ, Dargie HJ. Circulating endothelin in acute ischemic syndromes. Br Heart J 1992 ; 67 : 383-6.
39. Ameli S, Kaul S, Castro L, Arora C, Mirea A, Shah PK. Effect of percutaneous transluminal coronary angioplasty on circulating endothelin levels. Am J Cardiol 1993 ; 72 : 1352-6.
40. Zeiher AM, Goebel H, Schachinger V, Ihling C. Tissue endothelin-1 immunoreactivity in the active coronary atherosclerotic plaque. A clue to the mechanism of increased vasoreactivity of the culprit lesion in unstable angina. Circulation 1995 ; 91 : 941-7.
41. Omland T, Terje Rie R, Aakvaag A, Aarsland T, Dickstein K. Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation 1994 ; 89 : 1573-9.
42. Pernow J, Kaijser L, Luindberg JM, Ahlborg G. Comparable potent coronary constrictor effects of endothelin-1 and big endothelin-1 in humans. Circulation 1996 ; 94 : 2077-82.
43. Grover GJ, Dzwonczyk S, Parham CS. The endothelin-1 receptor antagonist BQ-123 reduces infarct size in a canine model of coronary occlusion and reperfusion. Cardiovasc Res 1993 ; 27 : 1613-8.
44. Stewart DJ, Levy RD, Cernacek P, Langleben D. Increased plasma endothelin-1 in pulmonary hypertension: Marker or mediator of disease? Ann Intern Med 1991 ; 114 : 464-9.
45. Druml W, Steltzer H, Waldhausl W, Lenz K, Hammerle A, Vierhapper H, et al. Endothelin-1 in adult respiratory distress syndrome. Am Rev Respir Dis 1993 ; 148 : 1169-73.
46. Langleben D, DeMarchie M, Laporta D, Spanier AH, Schlesinger RD, Stewart DJ. Endothelin-1 in acute lung injury and the adult respiratory distress syndrome. Am Rev Respir Dis 1993 ; 148 : 1646-50.
47. Eddahibi S, Springall D, Mannan M, Carville C, Chabrier PE, Levame M, et al. Dilator effect of endothelins in pulmonary circulation: Changes associated with chronic hypoxia. Am J PhySiol 1993 ; 265 : L571-L80.
48. Eddahibi S, Raffestin B, Clozel M, Levame M, Adnot S. Protection from pulmonary hypertension with an orally active endothelin receptor antagonist in hypoxic rats. Am J Physiol 1995 ; 268 : H828-H35.
49. Zamora MA, Dempsey EC, Walchak SJ, Stelzner TJ. BQ123, an ETA receptor antagonist, inhibits endothelin-1-mediated proliferation of human pulmonary artery smooth muscle cells. Am J Respir Cell Mol Biol 1993 ; 9 : 429-33.
50. Zamora MR, O'Brien RF, Rutherford RB, Weil JV. Serum endothelin-1 concentrations and cold provocation in primary Raynaud's phenomenon. Lancet 1990 ; 336 : 1144-7.
51. Kanno K, Irata Y, Emori T, Ohta K, Shichiri M, Shinohara S. et al. Endothelin and Raynaud's phenomenon. Am J Med 1991 ; 90 : 130-2.
52. Dörffler-Melly J, Lüscher TF, Wenk M, Wen S, Bollinger A, Franzeck UK. Endothelin-1 and cold provocation in health, primary Raynaud's phenomenon, and progressive systemic sclerosis. Microvasc Res 1996 ; 52 : 193-7.
53. Kadono T, Kikuchi K, Sato S, Soma Y, Tamaki K, Takehara K. Elevated plasma endothelin levels in systemic sclerosis. Arch Dermatol Res 1995 ; 287 : 439-42.
54. Bottomley W, Goodfield M. A pathogenic role for endothelin in Raynaud's phenomenon? Acta Dermatol Venereol 1994 ; 74 : 433-4.
55. Smith PJ, McQueen DS, Webb DJ. The effect of cooling on the contractile response to endothelin-1 in small arteries from humans. J Cardiovasc Pharmacol 1995 ; 26 suppl 3 : 230-2.
56. Smith PJ, Ferro CJ, McQueen DS, Webb DJ. Functional studies in small arteries do not support a primary role for endothelin in the pathogenesis of Raynaud's disease. J Cardiovasc Pharmacol 1998 ; 31 suppl 1 : 473-6.
57. Knock GA, Terenghi G, Bunker CB, Bull HA, Dowd PM, Polak JM. Characterization of endothelin-binding sites in human skin and their regulation in primary Raynaud's phenomenon and systemic sclerosis. J Invest Dermatol 1993 ; 101 : 73-8.
58. Filep JG, Bodolay E, Sipka S, Gyimesi E, Csipö I, Szegedi G. Plasma endothelin correlates with antiendothelial antibodies in patients with mixed connective tissue disease. Circulation 1995 ; 92 : 2969-74.